β‐Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment

Abstract

β-Secretase (BACE1) is a major drug target for combating Alzheimer's disease (AD). Here we show that BACE1(-/-) mice develop significant retinal pathology including retinal thinning, apoptosis, reduced retinal vascular density and an increase in the age pigment, lipofuscin. BACE1 expression is highest in the neural retina while BACE2 was greatest in the retinal pigment epithelium (RPE)/choroid. Pigment epithelial-derived factor, a known regulator of γ-secretase, inhibits vascular endothelial growth factor (VEGF)-induced in vitro and in vivo angiogenesis and this is abolished by BACE1 inhibition. Moreover, intravitreal administration of BACE1 inhibitor or BACE1 small interfering RNA (siRNA) increases choroidal neovascularization in mice. BACE1 induces ectodomain shedding of vascular endothelial growth factor receptor 1 (VEGFR1) which is a prerequisite for γ-secretase release of a 100 kDa intracellular domain. The increase in lipofuscin following BACE1 inhibition and RNAI knockdown is associated with lysosomal perturbations. Taken together, our data show that BACE1 plays a critical role in retinal homeostasis and that the use of BACE inhibitors for AD should be viewed with extreme caution as they could lead to retinal pathology and exacerbate conditions such as age-related macular degeneration.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 36

1. 1.

   Anderson DH, Talaga KC, Rivest AJ, Barron E, Hageman GS, Johnson LV. Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Exp Eye Res. 2004;78:243-256.

   Not in our library10.1016/j.exer.2003.10.011

2. 2.

   Bjorklund C, Oscarson S, Benkestock K, Borkakoti N, Jansson K, Lindberg J, Vrang L, Hallberg A, Rosenquist A, Samuelsson B. Design and synthesis of potent and selective BACE-1 inhibitors. J Med Chem. 2010;53:1458-1464.

   Not in our library10.1021/jm901168f

3. 3.

   Boulton M, McKechnie NM, Breda J, Bayly M, Marshall J. The formation of autofluorescent granules in cultured human RPE. Invest Ophthalmol Vis Sci. 1989;30:82-89.

   Not in our library

4. 4.

   Boulton ME, Cai J, Grant MB, Zhang Y. Gamma-secretase regulates VEGFR-1 signalling in vascular endothelium and RPE. Adv Exp Med Biol. 2008a;613:313-319.

   Not in our library10.1007/978-0-387-74904-4_36

5. 5.

   Boulton ME, Cai J, Grant MB. γ-Secretase: a multifaceted regulator of angiogenesis. J Cell Mol Med. 2008b;12:781-795.

   Not in our library10.1111/j.1582-4934.2008.00274.x

6. 6.

   Brunner S, Skosyrski S, Kirschner-Schwabe R, Knobeloch KP, Neidhardt J, Feil S, Glaus E, Luhmann UF, Ruther K, Berger W, et al. Cone versus rod disease in a mutant Rpgr mouse caused by different genetic backgrounds. Invest Ophthalmol Vis Sci. 2010;51:1106-1115.

   Not in our library10.1167/iovs.08-2742

7. 7.

   Caballero S, Swaney J, Moreno K, Afzal A, Kielczewski J, Stoller G, Cavalli A, Garland W, Hansen G, Sabbadini R, et al. Anti-sphingosine-1-phosphate monoclonal antibodies inhibit angiogenesis and sub-retinal fibrosis in a murine model of laser-induced choroidal neovascularization. Exp Eye Res. 2009;88:367-377.

   Not in our library10.1016/j.exer.2008.07.012

8. 8.

   Cai J, Jiang WG, Grant MB, Boulton ME. Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem. 2006;281:3604-3613.

   Not in our library10.1074/jbc.m507401200

9. 9.

   Cai J, Wu L, Qi X, Li Calzi S, Caballero S, Shaw L, Ruan Q, Grant MB, Boulton ME. PEDF regulates vascular permeability by a gamma-secretase-mediated pathway. PLoS One. 2011a;6:e21164.

   Not in our library10.1371/journal.pone.0021164

10. 10.

    Cai J, Chen Z, Ruan Q, Han S, Liu L, Qi X, Boye SL, Hauswirth WW, Grant MB, Boulton ME. Gamma-secretase and presenilin mediate cleavage and phosphorylation of vascular endothelial growth factor receptor-1. J Biol Chem. 2011b;286:42514-42523.

    Not in our library10.1074/jbc.m111.296590

11. 11.

    Cai J, Wu L, Qi X, Shaw L, Li Calzi S, Caballero S, Jiang WG, Vinores SA, Antonetti D, Ahmed A, et al. Placenta growth factor-1 exerts time-dependent stabilization of adherens junctions following VEGF-induced vascular permeability. PLoS One. 2011c;6:e18076.

    Not in our library10.1371/journal.pone.0018076

12. 12.

    De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol. 2010;6:99-107.

    Not in our library10.1038/nrneurol.2009.218

13. 13.

    Ding JD, Johnson LV, Herrmann R, Farsiu S, Smith SG, Groelle M, Mace BE, Sullivan P, Jamison JA, Kelly U, et al. Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. Proc Natl Acad Sci USA. 2011;108:E279-E287.

    Not in our library10.1073/pnas.1100901108

14. 14.

    Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, Serneels L, Camacho IE, Marjaux E, Craessaerts K, et al. Phenotypic and biochemical analyses of BACE1-and BACE2-deficient mice. J Biol Chem. 2005;280:30797-30806.

    Not in our library10.1074/jbc.m505249200

15. 15.

    Jarrett SG, Boulton ME. Antioxidant up-regulation and increased nuclear DNA protection play key roles in adaptation to oxidative stress in epithelial cells. Free Radic Biol Med. 2005;38:1382-1391.

    Not in our library10.1016/j.freeradbiomed.2005.02.003

16. 16.

    Klaver DW, Wilce MC, Cui H, Hung AC, Gasperini R, Foa L, Small DH. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions. Biol Chem. 2010;391:849-859.

    Not in our library10.1515/bc.2010.089

17. 17.

    May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, Monk SA, Mathes BM, Mergott DJ, Watson BM, et al. Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor. J Neurosci. 2011;31:16507-16516.

    Not in our library10.1523/jneurosci.3647-11.2011

18. 18.

    Pasternak SH, Callahan JW, Mahuran DJ. The role of the endosomal/lysosomal system in amyloid-beta production and the pathophysiology of Alzheimer's disease: reexamining the spatial paradox from a lysosomal perspective. J Alzheimer Dis. 2004;6:53-65.

    Not in our library10.3233/jad-2004-6107

19. 19.

    Qi X, Hauswirth WW, Guy J. Dual gene therapy with extracellular superoxide dismutase and catalase attenuates experimental optic neuritis. Mol Vis. 2007a;13:1-11.

    Not in our library

20. 20.

    Qi X, Sun L, Lewin AS, Hauswirth WW, Guy J. Long-term suppression of neurodegeneration in chronic experimental optic neuritis: antioxidant gene therapy. Invest Ophthalmol Vis Sci. 2007b;48:5360-5370.

    Not in our library10.1167/iovs.07-0254

21. 21.

    Rahimi N. VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. Front Biosci. 2006;11:818-829.

    Not in our library10.2741/1839

22. 22.

    Rahimi N, Golde TE, Meyer RD. Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells. Cancer Res. 2009;15:2607-2614.

    Not in our library10.1158/0008-5472.can-08-2905

23. 23.

    Rakoczy PE, Baines M, Kennedy CJ, Constable IJ. Correlation between autofluorescent debris accumulation and the presence of partially processed forms of cathepsin D in cultured retinal pigment epithelial cells challenged with rod outer segments. Exp Eye Res. 1996;63:159-167.

    Not in our library10.1006/exer.1996.0104

24. 24.

    Sealy JM, Truong AP, Tso L, Probst GD, Aquino J, Hom RK, Jagodzinska BM, Dressen D, Wone DW, Brogley L, et al. Design and synthesis of cell potent BACE-1 inhibitors: structure-activity relationship of P1' substituents. Bioorg Med Chem Lett. 2009;19:6386-6391.

    Not in our library10.1016/j.bmcl.2009.09.061

25. 25.

    Sengupta N, Caballero S, Sullivan SM, Chang LJ, Afzal A, Li Calzi S, Kielczewski JL, Prabarakan S, Ellis EA, Moldovan L, et al. Regulation of adult hematopoietic stem cells fate for enhanced tissue-specific repair. Mol Ther. 2009;17:1594-1604.

    Not in our library10.1038/mt.2009.145

26. 26.

    Shaw LC, Pan H, Afzal A, Calzi SL, Spoerri PE, Sullivan SM, Grant MB. Proliferating endothelial cell-specific expression of IGF-I receptor ribozyme inhibits retinal neovascularization. Gene Ther. 2006;13:752-760.

    Not in our library10.1038/sj.gt.3302718

27. 27.

    Solans A, Estivill X, de La Luna S. A new aspartyl protease on 21q22.3, BACE2, is highly similar to Alzheimer's amyloid precursor protein beta-secretase. Cytogenet Cell Genet. 2000;89:177-184.

    Not in our library10.1159/000015608

28. 28.

    Sparrow JR, Boulton ME. RPE lipofuscin and its role in retinal pathobiology. Exp Eye Res. 2005;80:595-606.

    Not in our library10.1016/j.exer.2005.01.007

29. 29.

    Stachel SJ, Coburn CA, Steele TG, Jones KG, Loutzenhiser EF, Gregro AR, Rajapakse HA, Lai MT, Crouthamel MC, Xu M, et al. Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1). J Med Chem. 2004;47:6447-6450.

    Not in our library10.1021/jm049379g

30. 30.

    Tombran-Tink J. The neuroprotective and angiogenesis inhibitory serpin, PEDF: new insights into phylogeny, function, and signaling. Front Biosci. 2005;10:2131-2149.

    Not in our library10.2741/1686

31. 31.

    Vassar R, Kovacs DM, Yan R, Wong PC. The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J Neurosci. 2009;29:12787-12794.

    Not in our library10.1523/jneurosci.3657-09.2009

32. 32.

    Wassell J, Ellis S, Burke J, Boulton ME. Fluorescence properties of autofluorescent granules generated by cultured human RPE cells. Invest Ophthalmol Vis Sci. 1998;39:1487-1492.

    Not in our library

33. 33.

    Woo HN, Baik SH, Park JS, Gwon AR, Yang S, Yun YK, Jo DG. Secretases as therapeutic targets for Alzheimer's disease. Biochem Biophys Res Commun. 2011;404:10-15.

    Not in our library10.1016/j.bbrc.2010.11.132

34. 34.

    Wu FT, Stefanini MO, Mac Gabhann F, Kontos CD, Annex BH, Popel AS. A systems biology perspective on sVEGF R1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med. 2010;14:528-552.

    Not in our library10.1111/j.1582-4934.2009.00941.x

35. 35.

    Xiong K, Cai H, Luo XG, Struble RG, Clough RW, Yan XX. Mitochondrial respiratory inhibition and oxidative stress elevate beta-secretase (BACE1) proteins and activity in vivo in the rat retina. Exp Brain Res. 2007;181:435-446.

    Not in our library10.1007/s00221-007-0943-y

36. 36.

    Yoshida T, Ohno-Matsui K, Ichinose S, Sato T, Iwata N, Saido TC, Hisatomi T, Mochizuki M, Morita I, et al. The potential role of amyloid beta in the pathogenesis of age-related macular degeneration. J Clin Invest. 2005;115:2793-2800.

    Not in our library10.1172/jci24635

Cited by papers we hold 8

• Alzheimer’s Retinopathy: Seeing Disease in the Eyes · 2020
  No notice
• The physiological roles of tau and Aβ: implications for Alzheimer’s disease pathology and therapeutics · 2020
  No notice
• Brain expression of the vascular endothelial growth factor gene family in cognitive aging and alzheimer’s disease · 2019
  No notice
• The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease · 2018
  No notice
• Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors · 2016
  Not checked
• An aberrant sugar modification of BACE1 blocks its lysosomal targeting in Alzheimer's disease · 2015
  No notice
• BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease · 2014
  No notice
• The Alzheimer’s β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques · 2013
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.